Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-101 + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- Ascenta Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**AT-101 + docetaxel + prednisone** is an experimental combination therapy used in oncology clinical trials, primarily investigated in metastatic castration-resistant prostate cancer and other advanced solid malignancies. AT-101 (R-(-)-gossypol acetic acid) is a small molecule, oral BH3 mimetic that inhibits anti-apoptotic Bcl-2 family proteins, promoting caspase activation and apoptosis in tumor cells. Docetaxel is a microtubule inhibitor that disrupts cell division, while prednisone is a corticosteroid with anti-inflammatory and immunosuppressive effects and is often used in prostate cancer regimens to mitigate symptoms and side effects. This combination aims to induce synergistic tumor cell killing through complementary mechanisms: mitochondrial apoptosis (AT-101), mitotic arrest (docetaxel), and hormonal/anti-inflammatory modulation (prednisone). Clinical trials have tested this triplet particularly in patients with advanced, treatment-refractory prostate cancer and observed some benefit, especially in high-risk subsets or patients with prolonged disease control, though overall efficacy was limited and tolerability was generally modest[1][4].
- Other names
- AT-101 + docetaxel + prednisone
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))Bcl-w (B-cell lymphoma 2-like 2)BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on AT-101 + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-101 + docetaxel + prednisone.